Crossmark

PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma

Crossref DOI link: https://doi.org/10.1007/s00405-022-07571-9

Published Online: 2022-07-30

Published Print: 2023-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mo, Dun-Chang https://orcid.org/0000-0003-1316-2810
Huang, Jian-Feng

Luo, Peng-Hui

Chen, Long

Zou, Biao

Wang, Han-Lei
License Information

Text and Data Mining valid from 2022-07-30

Version of Record valid from 2022-07-30
More Information

Article History

Received: 1 July 2022

Accepted: 22 July 2022

First Online: 30 July 2022

Declarations

:

: The authors declare that they have no conflict of interest.

: Not applicable.

Document is current

Any future updates will be listed below